Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-154 versus placebo in biologic/targeted synthetic DMARD inadequate responder rheumatoid arthritis
NL-OMON51197Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ABBV-154 in rheumatoid arthritis (RA) (3 arms), sponsored by AbbVie Inc. Primary endpoint: ACR50 at Week 12. Planned start Jul 2021; status: withdrawn.
02
Drugs
ABBV-154
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON51197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51197.